title: Antibody persistence of two pentavalent DTwP-HB-Hib vaccines to the age of 15-18 months, and response to the booster dose of quadrivalent DTwP-Hib vaccine.
abstract: OBJECTIVE
  Antibody persistence in children following three doses of primary vaccination with diphtheria, tetanus, whole-cell-pertussis (DTwP), hepatitis B, and Haemophilus influenzae type b (Hib) vaccines (SIIL Pentavac vaccine vs. Easyfive(®) of Panacea Biotec), and response to the booster dose of DTwP-Hib (Quadrovax(®)) vaccine.
  
  
  METHODS
  Children who completed their primary immunization were assessed for antibodies at 15-18 months of age, and then given a booster dose of DTwP-Hib vaccine. Reactogenicity and safety of the booster dose was evaluated.
  
  
  RESULTS
  Both pentavalent vaccines demonstrated a good immune response at 15-18 months. Following the booster dose, all vaccinated subjects achieved protective titers against diphtheria, tetanus and Hib, whereas the response to pertussis antigen was ~78%. Fever and irritability was noted in 24%, local pain in 51%, and swelling in 36% of the children following booster dose.
  
  
  CONCLUSIONS
  Primary immunization with either pentavalent vaccine induced an excellent immunity lasting till the second year of life. A booster dose with DTwP-Hib (Quadrovax(®)) vaccine effectuated a good anamnestic response to all vaccine components, being specially strong for Hib in children previously vaccinated with SIIL liquid pentavalent vaccine (Pentavac(®)). Also, the safety profile of SIIL quadrivalent vaccine (Quadrovax(®)) administered as booster dose was acceptable.
authors.affiliation: Serum Institute of India Ltd., Pune, India. drhjs@seruminstitute.com
authors.forename: Hitt
authors.initials: H
authors.lastname: Sharma
authors.forename: Sangeeta
authors.initials: S
authors.lastname: Yadav
authors.forename: Sanjay
authors.initials: S
authors.lastname: Lalwani
authors.forename: Subhash
authors.initials: S
authors.lastname: Kapre
authors.forename: Suresh
authors.initials: S
authors.lastname: Jadhav
authors.forename: Sameer
authors.initials: S
authors.lastname: Parekh
authors.forename: Sonali
authors.initials: S
authors.lastname: Palkar
authors.forename: Satish
authors.initials: S
authors.lastname: Ravetkar
authors.forename: Sunil
authors.initials: S
authors.lastname: Bahl
authors.forename: Rakesh
authors.initials: R
authors.lastname: Kumar
authors.forename: Sunil
authors.initials: S
authors.lastname: Shewale
mesh_terms: D000907:Antibodies, Bacterial / Q000097:blood*; D000914:Antibodies, Viral / Q000097:blood*; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D064420:Drug-Related Side Effects and Adverse Reactions / Q000453:epidemiology / Q000473:pathology; D018073:Haemophilus Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D017325:Hepatitis B Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D006801:Humans; D007223:Infant; D013997:Time Factors; D014611:Vaccination / Q000379:methods
chemical_list: D000907:Antibodies, Bacterial; D000914:Antibodies, Viral; D015721:Diphtheria-Tetanus-Pertussis Vaccine; C524361:DtwP-HepB-Hib vaccine; D018073:Haemophilus Vaccines; D017325:Hepatitis B Vaccines